American Invest Hub
  • Politics
  • Investing
  • Business
  • Latest News

American Invest Hub

  • Politics
  • Investing
  • Business
  • Latest News
Business

Regeneron stock crashes on COPD data: here’s why I’m buying REGN today

by admin May 31, 2025
May 31, 2025
Regeneron stock crashes on COPD data: here’s why I’m buying REGN today

Regeneron Pharmaceuticals Inc (NASDAQ: REGN) crashed more than 15% this morning on disappointing data from Phase 3 trials of its experimental drug itepekimab.

Itepekimab is a drug candidate for chronic obstructive pulmonary disease (COPD) that the biotech firm developed with Paris headquartered Sanofi.

Including today’s plummet, REGN shares are down nearly 35% versus their year-to-date high.

Regeneron stock is going for a huge discount

Despite an unusually difficult first half of 2025, there’s ample reason, including solid fundamentals, to buy Regeneron stock at current levels.  

In 2024, the pharmaceutical behemoth reported $14.2 billion in revenue on $4.4 billion worth of net income, both ahead of consensus.

REGN’s net profit margin stood at just under 27% last year, underscoring its ability to generate substantial earnings from its operations.

From a valuation standpoint, Regeneron shares appear attractive as well.

They’re now going for a price-to-earnings multiple of less than 13 (trailing), well below their historical average and biotech sector median of about 27.

This discount suggests that markets may be undervaluing the company’s earnings potential and growth prospects at the time of writing.

REGN still has exposure to the COPD market

While itepekimab late-stage trials miss the mark, Regeneron flagship product, Dupixent, already has FDA approval for the treatment of COPD, marking its sixth US indication since initial approval for atopic dermatitis.

This suggests that REGN remains well-positioned in the respiratory conditions market even though its itepekimab disappointed on Friday.

Additionally, the biotechnology company spent $256 million earlier this month to buy 23andMe assets, which expand its footprint in genetic research and personalized medicine.

This said acquisition could bolster the company’s drug development pipeline and support long-term growth.

Note that Regeneron stock currently pays a dividend yield of 0.72% as well, which makes it somewhat more attractive to own in 2025.

How analysts recommend playing REGN shares

Investors should also note that analysts remain bullish on Regeneron shares despite the itepekimab setback today.

Citi analysts recently upgraded REGN stock to “buy”, citing stabilising fundamentals and near-term catalysts, including product developments, for instance, fianlimab.

On Friday, analysts at Cantor Fitzgerald also reiterated the biotech stock at “overweight”.

In a note to clients, the investment bank agreed that the disappointing late-stage data could hurt Regeneron for a while but expressed confidence in the firm’s long-term trajectory.

Cantor currently has a $695 price target on Regeneron Pharmaceuticals that indicates potential for a more than 40% upside from current levels.

All in all, while the trial results for itepekimab have introduced short-term volatility, the Nasdaq listed firm’s strong financials, diversified product portfolio, and strategic initiatives position it well for sustained growth moving forward.

Therefore, the company’s current stock price, reflecting a significant discount, offers a potential entry point for investors seeking exposure to a resilient and innovative biotech name.

The post Regeneron stock crashes on COPD data: here’s why I’m buying REGN today appeared first on Invezz

0
FacebookTwitterGoogle +Pinterest
previous post
US picks Palantir as data analysis partner, but why you shouldn’t jump into PLTR
next post
Why are investors concerned about Marvell’s custom AI chips business?

Related Posts

Is ServiceNow stock a buy or a sell...

April 18, 2025

Is Trump’s Truth Social now worth the same...

October 30, 2024

eBay stock price forecast: will it rise or...

February 25, 2025

Starbucks (SBUX) stock dips on Q2 miss: analysts...

April 30, 2025

Top 4 defensive stocks to buy and hold...

March 30, 2025

Stocks close higher, clawing back some losses from...

August 12, 2024

China signals openness to US trade talks as...

May 2, 2025

Who could buy TikTok in the US? Top...

January 25, 2025

Long ALGM: Rounding Bottom Formation and Strong Fundamentals...

January 6, 2025

Here’s why the DAX index has surged to...

December 6, 2024

    Stay updated with the latest news, exclusive offers, and special promotions. Sign up now and be the first to know! As a member, you'll receive curated content, insider tips, and invitations to exclusive events. Don't miss out on being part of something special.


    By opting in you agree to receive emails from us and our affiliates. Your information is secure and your privacy is protected.

    Latest News

    • Interview: Strategic location gives Brazil Potash cost advantage in domestic fertiliser market, says CEO Matt Simpson

      June 1, 2025
    • Canada’s Q1 GDP expands by 2.2%, driven by exports spike ahead of potential US tariffs

      June 1, 2025
    • President Trump to host farewell for Elon Musk as DOGE leader steps away

      June 1, 2025
    • UK’s digital banks face divergent fortunes: Starling stumbles, Monzo and Revolut soars

      June 1, 2025
    • Trump wants Apple to shift iPhone production from India to the US: here’s what it means

      May 18, 2025

    Categories

    • Business (2,982)
    • Investing (2,444)
    • Latest News (1,994)
    • Politics (1,530)
    • About us
    • Contact us
    • Privacy Policy
    • Terms & Conditions

    Disclaimer: americaninvesthub.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.

    Copyright © 2025 americaninvesthub.com | All Rights Reserved